{
  "id": 10731314,
  "title": "TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?",
  "url": "https://urgent.news/2026/09/29/transmedics-director-david-weill-purchases-109-000-of-stock-should",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-29T16:17:34.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/coverage/filings/2026/09/29/transmedics-director-david-weill-purchases-usd109-000-of-stock-should-investors-buy-too/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "On September 11, 2026, TransMedics Group, Inc.'s Director David Weill acquired 1,336 shares of the company's common stock, as reported in the SEC Form 4 filing. The transaction had a total value of $109,000, based on the weighted average purchase price of $81.63 per share. Post-transaction, the market value of the stock increased marginally to $82.18 per share by the market close on the same day.\n\nTransMedics Group is a commercial-stage medical technology enterprise operating within the $2.7 billion market capitalization range. The company's annual revenues, known as Trailing Twelve Months (TTM), amount to $668.5 million, showcasing its significant presence in the organ transplantation technology sector.\n\nThe Organ Care System, a patented innovation by TransMedics, differentiates it from competitors. This system employs proprietary perfusion technology to simulate near-physiological conditions, effectively extending the viability window of donor organs. By doing so, TransMedics enables the utilization of expanded criteria donors and improves transplant outcomes, thereby providing a competitive edge in addressing the substantial global shortage of viable donor organs.\n\nGiven this context, the question arises: Should investors consider purchasing TransMedics Group stock following Weill's recent purchase? While Weill's individual transaction may not be indicative of broader market sentiment, it does signal confidence in the company's prospects. As always, investors are advised to conduct thorough due diligence and consider their investment objectives and risk tolerance before making any investment decisions.",
  "summary": "Weill's acquisition increased his direct holdings to 16,392 shares, valued at $1.4 million at recent market prices, amid a 30% decline in the stock over the past year.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?",
        "url": "https://urgent.news/2026/09/29/transmedics-director-david-weill-purchases-109-000-of-stock-should-10740089",
        "published": "2026-09-29T16:37:34.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}